AbbVie's Lung Cancer Study Shows Encouraging Clinical Benefi

AbbVie Inc (NYSE: ABBV) announced topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, 

Related Keywords

, Abbvie Inc , Met High , Met Intermediate ,